Cytokines are small proteins produced by a broad range of cells important in cell signaling. They include interleukins, but also chemokines, interferons, and tumor necrosis factors (TNF). They play an important role for communication between cells of the innate and adaptive immune system. The cytokine network is complex and, therefore, therapeutic interventions are difficult. The first anti-cytokine strategy successfully introduced into IBD therapy was the neutralization of TNF by antibodies. Beyond targeting this cytokine anti-IL-23 strategies were demonstrated to be of therapeutic benefit in IBD. Anti-IL-6 strategies seem to have clinical potential but also cause some risk for the patient due to the lack of CRP increase upon severe inflammation. JAK inhibitors target the intracellular signaling of several cytokine receptors and represent a promising class of broader and somewhat unspecific anti-cytokine strategies. Many other anti-cytokine approaches have failed due to the redundant nature of the cytokine network. Whether further anti-cytokines strategies have potential for IBD treatment may be evaluated in future studies.

Keywords:
Inflammatory bowel disease, Pathophysiology, Environmental factors, Hygiene hypothesis
1.
D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116:1029-1034.
2.
Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035.
3.
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405.
4.
Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-769.
5.
Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-333; quiz 591.
6.
Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
7.
Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S; PRECISE 1 Study Investigators: Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-238.
8.
Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ; PRECISE 2 Study Investigators: Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-250.
9.
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.
10.
Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-787.
11.
Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB: Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-265.e1-e3.
12.
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P; PURSUIT-SC Study Group: Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85-95; quiz e14-e15.
13.
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P; PURSUIT-Maintenance Study Group: Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96-109.e1.
14.
Rutgeerts P: Infliximab is the drug we have been waiting for in Crohn's disease. Inflamm Bowel Dis 2000;6:132-136.
15.
Rutgeerts P, Van Assche G, Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-1610.
16.
Blandizzi C, Gionchetti P, Armuzzi A, Caporali R, Chimenti S, Cimaz R, Cimino L, Lapadula G, Lionetti P, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Girolomoni G: The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 2014;27(1 suppl):1-10.
17.
Nielsen OH, Ainsworth MA: Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 2013;369:754-762.
18.
Sands BE: Why do anti-tumor necrosis factor antibodies work in Crohn's disease? Rev Gastroenterol Disord 2004;4(suppl 3):S10-S17.
19.
Papadakis KA, Targan SR: Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000;119:1148-1157.
20.
Dinarello CA: Interleukin-1 and tumor necrosis factor: effector cytokines in autoimmune diseases. Semin Immunol 1992;4:133-145.
21.
Baert FJ, Rutgeerts PR: Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int J Colorectal Dis 1999;14:47-51.
22.
Chevaux JB, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L: Mucosal healing with anti-TNF antibodies. Digestion 2012;86(suppl 1):16-22.
23.
Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, Mottet C, Burnand B, Froehlich F; Swiss Inflammatory Bowel Disease Cohort Study Group: Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease. Digestion 2013;87:212-221.
24.
Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-Biroulet L, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group: Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. Aliment Pharmacol Ther 2015;42:977-989.
25.
van den Heuvel TR, Jonkers DM, Jeuring SF, Romberg-Camps MJ, Oostenbrug LE, Zeegers MP, Masclee AA, Pierik MJ: Cohort profile: the inflammatory bowel disease South Limburg cohort (IBDSL). Int J Epidemiol 2015;pii:dyv088.
26.
Jeuring SF, Van den Heuvel T, Zeegers M, Hameeteman W, Romberg-Camps M, Oostenbrug LE, Masclee Ad, Jonkers D, Pierik MJ: Disease behavior in Crohn's disease patients diagnosed in the biological era - a Dutch population-based IBD-SL cohort study. Gastroenterology 2015;148:S22-S23.
27.
Scharl M, Rogler G: Pathophysiology of fistula formation in Crohn's disease. World J Gastrointest Pathophysiol 2014;5:205-212.
28.
Lawrance IC, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, Reif S, Speca S, Latella G: Cellular and molecular mediators of intestinal fibrosis. J Crohns Colitis 2015;pii:j.crohns.2014.09.008.
29.
Fiocchi C: Genes and ‘in-vironment': how will our concepts on the pathophysiology of inflammatory bowel disease develop in the future? Dig Dis 2012;30(suppl 3):2-11.
30.
Rogler G: Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 2004;20:311-317.
31.
Rogler G: Interaction between susceptibility and environment: examples from the digestive tract. Dig Dis 2011;29:136-143.
32.
Scharl M, Rogler G: Inflammatory bowel disease pathogenesis: what is new? Curr Opin Gastroenterol 2012;28:301-309.
33.
Atreya R, Neurath MF: IBD pathogenesis in 2014: molecular pathways controlling barrier function in IBD. Nat Rev Gastroenterol Hepatol 2015;12:67-68.
34.
Watson AJ, Hughes KR: TNF-α-induced intestinal epithelial cell shedding: implications for intestinal barrier function. Ann N Y Acad Sci 2012;1258:1-8.
35.
Ehehalt R, Braun A, Karner M, Füllekrug J, Stremmel W: Phosphatidylcholine as a constituent in the colonic mucosal barrier - physiological and clinical relevance. Biochim Biophys Acta 2010;1801:983-993.
36.
Leucht K, Fischbeck A, Caj M, Liebisch G, Hartlieb E, Benes P, Fried M, Humpf HU, Rogler G, Hausmann M: Sphingomyelin and phosphatidylcholine contrarily affect the induction of apoptosis in intestinal epithelial cells. Mol Nutr Food Res 2014;58:782-798.
37.
Stremmel W, Ehehalt R, Staffer S, Stoffels S, Mohr A, Karner M, Braun A: Mucosal protection by phosphatidylcholine. Dig Dis 2012;30(suppl 3):85-91.
38.
Ehehalt R, Wagenblast J, Erben G, Lehmann WD, Hinz U, Merle U, Stremmel W: Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. Scand J Gastroenterol 2004;39:737-742.
39.
Karner M, Kocjan A, Stein J, Schreiber S, von Boyen G, Uebel P, Schmidt C, Kupcinskas L, Dina I, Zuelch F, Keilhauer G, Stremmel W: First multicenter study of modified release phosphatidylcholine ‘LT-02' in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol 2014;109:1041-1051.
40.
Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M: Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. J Clin Gastroenterol 2010;44:e101-e107.
41.
Stremmel W, Hanemann A, Braun A, Stoffels S, Karner M, Fazeli S, Ehehalt R: Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis - a review of three clinical trials. Expert Opin Investig Drugs 2010;19:1623-1630.
42.
Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R: Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005;54:966-971.
43.
Wehkamp J, Stange EF, Fellermann K: Defensin-immunology in inflammatory bowel disease. Gastroenterol Clin Biol 2009;33(suppl 3):S137-S144.
44.
Kübler I, Koslowski MJ, Gersemann M, Fellermann K, Beisner J, Becker S, Rothfuss K, Herrlinger KR, Stange EF, Wehkamp J: Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn's disease. Aliment Pharmacol Ther 2009;30:621-633.
45.
Bevins CL, Stange EF, Wehkamp J: Decreased Paneth cell defensin expression in ileal Crohn's disease is independent of inflammation, but linked to the NOD2 1007fs genotype. Gut 2009;58:882-883; discussion 883-884.
46.
Wehkamp J, Koslowski M, Wang G, Stange EF: Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. Mucosal Immunol 2008;1(suppl 1):S67-S74.
47.
Wang G, Stange EF, Wehkamp J: Host-microbe interaction: mechanisms of defensin deficiency in Crohn's disease. Expert Rev Anti Infect Ther 2007;5:1049-1057.
48.
Wehkamp J, Schmid M, Fellermann K, Stange EF: Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol 2005;77:460-465.
49.
Fellermann K, Wehkamp J, Herrlinger KR, Stange EF: Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol 2003;15:627-634.
50.
Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feathers RW, Chu H, Lima H Jr, Fellermann K, Ganz T, Stange EF, Bevins CL: Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005;102:18129-18134.
51.
Ruiz PA, Morón B, Becker HM, Lang S, Atrott K, Spalinger MR, Scharl M, Wojtal KA, Fischbeck-Terhalle A, Frey-Wagner I, Hausmann M, Kraemer T, Rogler G: Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome. Gut 2016;pii:gutjnl-2015-310297.
52.
Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, Peyrin-Biroulet L, Panes J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms LA, Seielstad M, Steinhart AH, Targan SR, van den Berg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcinskas L, Sventoraityte J, Mansfield JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotter JI, Mathew CG, Griffiths AM, Gearry R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246-252.
53.
Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panes J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M: Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-1125.
54.
Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Buning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD Genetics Consortium (IIBDGC), Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-124.
55.
Neurath MF: Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014;14:329-342.
56.
Vicini P, Fields O, Lai E, Litwack ED, Martin AM, Morgan TM, Pacanowski MA, Papaluca M, Perez OD, Ringel MS, Robson M, Sakul H, Vockley J, Zaks T, Dolsten M, Sogaard M: Precision medicine in the age of big data: the present and future role of large-scale unbiased sequencing in drug discovery and development. Clin Pharmacol Ther 2016;99:198-207.
57.
Aronson SJ, Rehm HL: Building the foundation for genomics in precision medicine. Nature 2015;526:336-342.
58.
Lopez J, Harris S, Roda D, Yap TA: Precision medicine for molecularly targeted agents and immunotherapies in early-phase clinical trials. Transl Oncogenomics 2015;7(suppl 1):1-11.
59.
Rappaport SM: Genetic factors are not the major causes of chronic diseases. PLoS One 2016;11:e0154387.
60.
Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF: How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med 2013;19:822-824.
61.
Andoh A, Yagi Y, Shioya M, Nishida A, Tsujikawa T, Fujiyama Y: Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 2008;14:5154-5161.
62.
Fuss IJ: Cytokine network in inflammatory bowel disease. Curr Drug Targets Inflamm Allergy 2003;2:101-112.
63.
Scharl M, Vavricka SR, Rogler G: Review: new anti-cytokines for IBD: what is in the pipeline? Curr Drug Targets 2013;14:1405-1420.
64.
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group: Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367:1519-1528.
65.
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P; Ustekinumab Crohn's Disease Study Group: A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135:1130-1141.
66.
Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Grimaud JC, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif: Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn's disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol 2016;14:242-250.e1-e2.
67.
Feagan BG, Gasink C, Lang Y, Friedman JR, Johanns J, Gao LL, Sands B, Hanauer S, Rutgeerts P, Targan S, Ghosh S, de Villiers W, Colombel JF, Tulassay Z, Seidler U, Sandborn WJ: A multicenter, randomized, double-blind, placebo-controlled phase 3 study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately severe active Crohn's disease who are naïve or not refractory to anti-TNFα: uniti-2. United European Gastroenterol J 2015:abstract LB4.
68.
Sands BE, Chen J, Penney M, Newbold P, Faggioni R, van der Merwe R, Patra K, Klekotka P, Pulkstenis E, Drappa J, Gasser RA: Initial evaluation of MEDI2070 (specific anti-IL-23 antibody) in patients with active Crohn's disease who have failed anti-TNF antibody therapy: a randomized, double-blind placebo-controlled phase 2a induction study. Gastroenterology 2015;148:S163-S164.
69.
Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF: From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-554.
70.
Rossi JF, Lu ZY, Jourdan M, Klein B: Interleukin-6 as a therapeutic target. Clin Cancer Res 2015;21:1248-1257.
71.
Wolf J, Rose-John S, Garbers C: Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 2014;70:11-20.
72.
Tanaka T, Kishimoto T: The biology and medical implications of interleukin-6. Cancer Immunol Res 2014;2:288-294.
73.
Scheller J, Garbers C, Rose-John S: Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 2014;26:2-12.
74.
Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, Yao Y: Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 2014;141:125-139.
75.
Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-996; discussion 947.
76.
Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J, Schreiber SW: Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn's disease who are anti-tumour necrosis factor inadequate responders. J Crohns Colitis 2016:abstract OP015.
77.
Boland BS, Sandborn WJ, Chang JT: Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am 2014;43:603-617.
78.
Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W; Study A3921063 Investigators: Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-624.
79.
Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, Klopocka M, Goldis E, Wisniewska-Jarosinska M, Baranovsky A, Sike R, Tasset C, Van der Aa A, Harrison P: Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn's disease: interim analysis from the phase 2 FITZROY study. J Crohns Colitis 2016:abstract OP020.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.